Importance Obesity affects approximately 19% of women and 14% of men worldwide and is
associated with increased morbidity. Antiobesity medications (AOMs) modify biological …

The global prevalence of obesity has more than doubled over the past four decades,
currently affecting more than a billion individuals. Beyond its recognition as a high-risk …

Background Insufficient physical activity increases the risk of non-communicable diseases,
poor physical and cognitive function, weight gain, and mental ill-health. Global prevalence of …

Background Obesity is chronic disease and causal precursor to myriad other conditions,
including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was …

Background Diabetes can be detected at the primary health-care level, and effective
treatments lower the risk of complications. There are insufficient data on the coverage of …

Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with
type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo …

As the rates of obesity and type 2 diabetes (T2D) continue to increase globally, so does the
prevalence of metabolic dysfunction associated steatotic liver disease (MASLD). Currently …

Obesity, primarily characterized by excessive fat accumulation, is a multifactorial chronic
disease with an increasing global prevalence. Despite the well-documented epidemiology …

Over the past four decades, China has witnessed an important nutritional transition,
characterised by a heightened overnutrition burden among children. The country now has …

Medications for obesity have been studied in various populations over the past three
decades. We aimed to quantify the baseline demographic characteristics of BMI, sex, age …